SG10201912134TA - Methods and composition for the prediction of the activity of enzastaurin - Google Patents
Methods and composition for the prediction of the activity of enzastaurinInfo
- Publication number
- SG10201912134TA SG10201912134TA SG10201912134TA SG10201912134TA SG10201912134TA SG 10201912134T A SG10201912134T A SG 10201912134TA SG 10201912134T A SG10201912134T A SG 10201912134TA SG 10201912134T A SG10201912134T A SG 10201912134TA SG 10201912134T A SG10201912134T A SG 10201912134TA
- Authority
- SG
- Singapore
- Prior art keywords
- enzastaurin
- prediction
- activity
- composition
- methods
- Prior art date
Links
- AXRCEOKUDYDWLF-UHFFFAOYSA-N 3-(1-methyl-3-indolyl)-4-[1-[1-(2-pyridinylmethyl)-4-piperidinyl]-3-indolyl]pyrrole-2,5-dione Chemical compound C12=CC=CC=C2N(C)C=C1C(C(NC1=O)=O)=C1C(C1=CC=CC=C11)=CN1C(CC1)CCN1CC1=CC=CC=N1 AXRCEOKUDYDWLF-UHFFFAOYSA-N 0.000 title 1
- 229950002189 enzastaurin Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medical Treatment And Welfare Office Work (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662382734P | 2016-09-01 | 2016-09-01 | |
| US201662414601P | 2016-10-28 | 2016-10-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201912134TA true SG10201912134TA (en) | 2020-02-27 |
Family
ID=59923555
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912134TA SG10201912134TA (en) | 2016-09-01 | 2017-08-31 | Methods and composition for the prediction of the activity of enzastaurin |
| SG11201901762WA SG11201901762WA (en) | 2016-09-01 | 2017-08-31 | Methods and composition for the prediction of the activity of enzastaurin |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901762WA SG11201901762WA (en) | 2016-09-01 | 2017-08-31 | Methods and composition for the prediction of the activity of enzastaurin |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11421280B2 (enExample) |
| EP (1) | EP3507384B1 (enExample) |
| JP (3) | JP7197915B2 (enExample) |
| KR (1) | KR20190046935A (enExample) |
| CN (1) | CN109952383B (enExample) |
| AU (1) | AU2017318669B2 (enExample) |
| BR (1) | BR112019003951A2 (enExample) |
| CA (1) | CA3035386A1 (enExample) |
| JO (1) | JOP20190025A1 (enExample) |
| MX (1) | MX2019002377A (enExample) |
| PH (1) | PH12019500422A1 (enExample) |
| RU (1) | RU2019109011A (enExample) |
| SG (2) | SG10201912134TA (enExample) |
| TW (2) | TW202313973A (enExample) |
| WO (1) | WO2018045240A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190025A1 (ar) | 2016-09-01 | 2019-02-19 | Denovo Biopharma Llc | طرق وتركيبة لتوقع نشاط إنزاستورين |
| CN110496223B (zh) * | 2018-05-17 | 2021-09-10 | 复旦大学附属肿瘤医院 | 一种治疗非霍奇金氏淋巴瘤的药物组合物 |
| US20220193062A1 (en) * | 2018-09-12 | 2022-06-23 | Denovo Biopharma Llc | Combination of enzastaurin and inhibitors of btk and uses thereof |
| CN111549033B (zh) * | 2020-06-11 | 2021-02-12 | 南京市江宁医院 | 慢病毒感染人表皮角质细胞株及其构建方法和应用 |
| US11227690B1 (en) * | 2020-09-14 | 2022-01-18 | Opendna Ltd. | Machine learning prediction of therapy response |
| WO2023001178A1 (zh) * | 2021-07-23 | 2023-01-26 | 高雄医学大学 | 用于评估二代荷尔蒙药物治疗前列腺癌疗效的临床治疗药物预测和推荐系统及方法 |
| US20230131677A1 (en) * | 2021-10-21 | 2023-04-27 | Toyota Research Institute, Inc. | Systems and methods for predicting the effect of an intervention via machine learning |
| CN118339312A (zh) * | 2021-11-23 | 2024-07-12 | 索元生物医药(美国)有限公司 | 用于评估多核苷酸递送和癌疗法之功效的组合物和方法 |
| US12474842B2 (en) * | 2021-12-13 | 2025-11-18 | Google Llc | Optimizing data placement based on data temperature and lifetime prediction |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3998261B2 (ja) | 1993-12-23 | 2007-10-24 | イーライ・リリー・アンド・カンパニー | プロテインキナーゼｃ阻害剤 |
| JP2004512029A (ja) | 2000-08-16 | 2004-04-22 | カイロン コーポレイション | ヒト遺伝子および遺伝子発現産物 |
| US20040072217A1 (en) | 2002-06-17 | 2004-04-15 | Affymetrix, Inc. | Methods of analysis of linkage disequilibrium |
| CA2393720C (en) | 2002-07-12 | 2010-09-14 | Eli Lilly And Company | Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride |
| WO2007145992A2 (en) | 2006-06-05 | 2007-12-21 | Perlegen Sciences, Inc. | Genetic basis of treatment response in depression patients |
| EP2707498B1 (en) | 2011-01-31 | 2018-01-17 | Denovo Biomarkers Inc. | Method for discovering pharmacogenomic biomarkers |
| SG195191A1 (en) * | 2011-06-08 | 2013-12-30 | Denovo Biopharma Hangzhou Ltd Co | Methods and compositions of predicting activity of retinoid x receptor modulator |
| JOP20190025A1 (ar) | 2016-09-01 | 2019-02-19 | Denovo Biopharma Llc | طرق وتركيبة لتوقع نشاط إنزاستورين |
-
2017
- 2017-06-16 JO JOP/2019/0025A patent/JOP20190025A1/ar unknown
- 2017-08-31 WO PCT/US2017/049747 patent/WO2018045240A1/en not_active Ceased
- 2017-08-31 CA CA3035386A patent/CA3035386A1/en active Pending
- 2017-08-31 CN CN201780066737.5A patent/CN109952383B/zh active Active
- 2017-08-31 US US16/327,788 patent/US11421280B2/en active Active
- 2017-08-31 AU AU2017318669A patent/AU2017318669B2/en not_active Ceased
- 2017-08-31 JP JP2019512609A patent/JP7197915B2/ja active Active
- 2017-08-31 KR KR1020197009407A patent/KR20190046935A/ko not_active Ceased
- 2017-08-31 MX MX2019002377A patent/MX2019002377A/es unknown
- 2017-08-31 SG SG10201912134TA patent/SG10201912134TA/en unknown
- 2017-08-31 TW TW111122709A patent/TW202313973A/zh unknown
- 2017-08-31 EP EP17771623.0A patent/EP3507384B1/en active Active
- 2017-08-31 RU RU2019109011A patent/RU2019109011A/ru unknown
- 2017-08-31 BR BR112019003951A patent/BR112019003951A2/pt not_active IP Right Cessation
- 2017-08-31 SG SG11201901762WA patent/SG11201901762WA/en unknown
- 2017-08-31 TW TW106129838A patent/TWI771317B/zh not_active IP Right Cessation
-
2019
- 2019-02-27 PH PH12019500422A patent/PH12019500422A1/en unknown
-
2020
- 2020-08-26 JP JP2020142358A patent/JP2020188816A/ja active Pending
-
2022
- 2022-08-18 US US17/820,772 patent/US20230074781A1/en not_active Abandoned
- 2022-09-16 JP JP2022148064A patent/JP2022173308A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JOP20190025A1 (ar) | 2019-02-19 |
| JP2019528705A (ja) | 2019-10-17 |
| EP3507384B1 (en) | 2023-08-30 |
| SG11201901762WA (en) | 2019-03-28 |
| CA3035386A1 (en) | 2018-03-08 |
| TW202313973A (zh) | 2023-04-01 |
| AU2017318669B2 (en) | 2023-04-20 |
| MX2019002377A (es) | 2019-09-05 |
| CN109952383A (zh) | 2019-06-28 |
| JP2022173308A (ja) | 2022-11-18 |
| US20230074781A1 (en) | 2023-03-09 |
| US20190233902A1 (en) | 2019-08-01 |
| JP7197915B2 (ja) | 2022-12-28 |
| WO2018045240A1 (en) | 2018-03-08 |
| US11421280B2 (en) | 2022-08-23 |
| CN109952383B (zh) | 2024-01-05 |
| TW201812125A (zh) | 2018-04-01 |
| RU2019109011A3 (enExample) | 2021-01-22 |
| AU2017318669A1 (en) | 2019-03-07 |
| RU2019109011A (ru) | 2020-10-05 |
| KR20190046935A (ko) | 2019-05-07 |
| EP3507384A1 (en) | 2019-07-10 |
| JP2020188816A (ja) | 2020-11-26 |
| TWI771317B (zh) | 2022-07-21 |
| PH12019500422A1 (en) | 2019-05-27 |
| BR112019003951A2 (pt) | 2019-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286316A (en) | New micro-dystrophins and related method of use | |
| ZA201905677B (en) | Glycan-interacting compounds and methods of use | |
| IL266674A (en) | Preparations and methods for treating an opioid overdose | |
| IL258768A (en) | Compounds interacting with glycans and methods of use | |
| SG10201912134TA (en) | Methods and composition for the prediction of the activity of enzastaurin | |
| IL251724A0 (en) | Preparations and methods for treating meibomian gland dysfunction | |
| IL247515A0 (en) | Snekribirock for the treatment of leprosy | |
| HUE068842T2 (hu) | Vegyületek és alkalmazási eljárásaik | |
| IL259281B (en) | History of bipyrazolyl used in the treatment of autoimmune diseases | |
| IL254398A0 (en) | Antimicrobial compounds and methods for their preparation and use | |
| GB2544180B (en) | Cover means and method of use thereof | |
| GB201609786D0 (en) | Compounds and method of use | |
| SG11201702554QA (en) | Compositions and methods for the treatment of multiple sclerosis | |
| IL270011B (en) | Medicinal compounds and methods | |
| IL253617A0 (en) | Snekribirock for the treatment of leprosy | |
| PL3113774T3 (pl) | Kompozycje grapiprantu i sposoby ich zastosowania | |
| IL255819A (en) | An improved process for the preparation of sofosbuvir and intermediates | |
| IL248995A0 (en) | Methods for identifying substances that change the activity of irhom proteins and their use | |
| ZA201608823B (en) | Processes for the preparation of azd5363 and novel intermediate used therein | |
| IL251588A0 (en) | Methods and preparations for increasing the potency of antifungal agents | |
| GB201601514D0 (en) | New processes and compounds | |
| IL269681A (en) | New methods for treating multiple sclerosis | |
| SG11201706369PA (en) | Compositions and methods for the treatment of mucositis | |
| EP3212195A4 (en) | Compositions and methods for treating hiv-associated cognitive dysfunction | |
| SG11201704282UA (en) | Compositions and methods for the treatment of multiple sclerosis |